Prioritization of evidence-based indications for intravenous immunoglobulin

Journal of Clinical Immunology

Volumn 33, Issue 6, 2013, Pages 1033-1036

  Orange, Jordan S ^a   Ochs, Hans D ^b   Cunningham Rundles, Charlotte ^c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ALZHEIMER DISEASE; AUTISM; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD DONOR; CHRONIC IMMUNE DEMYELINATING POLYNEUROPATHY; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEALTH CARE PLANNING; HUMAN; HYPER IGM SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; LETTER; LYMPHOPROLIFERATIVE DISEASE; MENTAL DISEASE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOME ASSESSMENT; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCAL INFECTION; PEMPHIGUS VULGARIS; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; SEVERE COMBINED IMMUNODEFICIENCY; SPECIFIC ANTIBODY DEFICIENCY; SPONTANEOUS ABORTION; STREPTOCOCCUS INFECTION; TOXIC EPIDERMAL NECROLYSIS; UNITED KINGDOM; X LINKED AGAMMAGLOBULINEMIA;

ALGORITHMS; CLINICAL PROTOCOLS; EVIDENCE-BASED MEDICINE; HEALTH PLANNING TECHNICAL ASSISTANCE; HEALTH PRIORITIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; PRACTICE GUIDELINES AS TOPIC;

EID: 84880283616     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-013-9912-3     Document Type: Letter

References (16)

1. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525-53.
2. Constantine MM, Thomas W, Whitman L, Kahwash E, Dolan S, Smith S, et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion. 2007;47:2072-80. (Pubitemid 47623964)
3. Provan D, Chapel HM, Sewell WA, O'Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ. 2008;337:a1831.
4. Delforge M, Farber CM, Spath P, Kaveri S, Witte T, Misbah SA, et al. Recommended indications for the administration of polyclonal immunoglobulin preparations. Acta Clin Belg. 2011;66:346-60.
5. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs. 2010;70:513-28.
6. Solomon B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther. 2007;9:79-85. (Pubitemid 46508757)
7. Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol. 2009;19:90-8.
8. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G. Recommendations for the use of albumin and immunoglobulins. Blood Transfus. 2009;7:216-34.
9. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78:1009-15.
10. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin - reasons and possible solutions. Nat Clin Pract. 2007;3:120-1. (Pubitemid 46403934)
11. National Demand Mangament Programme for Immunoglobulin. http://www.ivig.nhs.uk/index.html Link active as of 1/11/13.
12. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61-70.
13. Simoens S. Pharmacoeconomics of immunoglobulins in primary immunodeficiency. Expert Rev Pharmacoecon Outcomes Res. 2009;9:375-86.
14. 2007. Hospital usage of intravenous immunoglobulin: A 2006 survey of pharmacy directors. http://primaryimmune.org/idf-survey-research-center/idf- surveys?aid=1369&sa=1 Link active as of 1/11/13.
15. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167:424-32.
16. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452-9. (Pubitemid 46702386)